Biotech, cancer, clinical trials

Dendreon Full Results Coming Tuesday

Luke Timmerman 4/24/09

Dendreon, the Seattle maker of an immune-stimulating therapy for prostate cancer, said today it will report the full results of a pivotal trial next week. The company already said the trial, called Impact, hit its main goal of helping men live longer, but the details will have to wait for a presentation at 2:20 pm Central time on April 28 at Room W375 in McCormick Place, the convention center in Chicago. Dendreon will hold a webcast to discuss the results further at 4:30 pm Central time that day.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.